Skip to main content

Advertisement

Table 2 Treatment characteristics

From: Dose escalation with stereotactic body radiation therapy boost for locally advanced non small cell lung cancer

  Mean, Median (Range)
Total Prescribed Dose (Gy) 76.4, 75.4 (65–90)
SBRT Prescription IDL (%) 80.8, 80.0 (70–92)
Number of Boost Fractions 5, 5, (5–5)
SBRT Dose per Fraction (Gy) 5, 5 (4–6)
Total Boost Dose 25, 25 (20–30)
Duration of SBRT Treatment 9, 7 (5–11)
Number of IMRT Fractions 27.6, 28, (25–30)
IMRT Dose per Fraction 1.87, 1.8 (1.8-2.0)
Total IMRT Dose 51.42, 50.40 (45–60)
Duration of IMRT treatment 41.5, 42 (35–49)
Duration between IMRT and SBRT 25, 20 (7–97)
Cumulative BED10 98.8, 97.0 (81.1-120)
Coverage 95.7, 96 (80–100)
NCI 1.53, 1.43 (1.23-2.10)
Chemotherapy (concurrent, sequential) (15, 1) (94%, 6%)
  1. Abbreviations: IDL Isodose Line, BED Biologically Effective Dose, NCI New Conformity Index, which is calculated by the formula: Treatment Volume × Prescription Isodose Line/(Volume of Target Covered by Prescription Isodose Line)2.